Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-05-08
2007-05-08
Page, Thurman K. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C546S229000
Reexamination Certificate
active
11270780
ABSTRACT:
This invention provides a compound of the formula (I):wherein R1represents a (C1–C6)alkyl group; R2represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group or a (C1–C6)alkoxy group; R3, R4, R5and R6each independently represents a hydrogen atom, a (C1–C6)alkyl, or a halogen atom; R7represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group optionally substituted with a piperidino group, a (C1–C6)alkoxy group optionally substituted with a 3–7 membered cycloalkyl ring, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group, a (C1–C6)alkoxy-(C1–C6)alkoxy group, a halo (C1–C6)alkyl group, a (C1–C6)alkylthio group, a (C1–C6)alkylsulfinyl group or a (C1–C6)alkylsulfonyl group; R8represents a (C1–C6)alkyl group, a halo(C1–C6)alkyl group, a (C1–C6)alkoxy group, a hydroxy(C1–C6)alkoxy group, a (C1–C6)alkoxy-(C1–C6)alkyl group or a (C1–C6)alkoxy-(C1–C6)alkoxy group; or R7and R8, when adjacent to each other, taken together with the carbon atoms to which they are attached form a 5–8 membered carbocyclic or heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents selected from the group consisting of a hydroxy group, a (C1–C6)alkyl group, a (C1–C6)alkoxy group and a hydroxy(C1–C6)alkyl group; and R9represents a hydrogen atom or a halogen atom; or a pharmaceutically acceptable salt or solvate thereof.These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor, such as pain or the like in mammalian. The present invention also provides a pharmaceutical composition comprising the compound of formula(I).
REFERENCES:
patent: WO 2002/16318 (2002-02-01), None
patent: WO 2002/16319 (2002-02-01), None
patent: WO 2004/035533 (2004-04-01), None
patent: WO 2005/003084 (2005-01-01), None
patent: WO 2005003084 (2005-01-01), None
J. Hogue, et al., “Pathophysiology and First-line Treatment of Osteoarthritis”, The Annal of Pharmacotherapy, Apr. 2002, pp. 679-686, vol. 36.
D. Grennan, et al., “Rheumatoid Arthritis”, Textbook of Pain, 1994, pp. 397-407.
R. Meyer, et al., “Peripheral Neural Mechanisms of Nociception”, Textbook of Pain, 1994, pp. 13-44.
J. Levine, et al., “Inflammatory Pain”, Textbook of Pain, 1994 pp. 45-56.
M. Millan, et al., “The Induction of Pain: An Inegrative Review”, Progress in Neurobiology, 1999, pp. 1-164, vol. 57.
C Woolf, et al., “Implications of Recent Advances in the Understanding of Pain Pathophysiology for the Assessment of Pain in Patients”, Pain Supplement 1999, pp. S141-S147, vol. 6.
C. Woolf, et al., “Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management”, The Lancet, Jun. 5, 1999, vol. 353.
C Woolf, et al., “Neuronal Plasticity: Increasing the Gain in Pain”, Science, Jun. 9, 2000, pp. 1765-1768, vol. 288.
Inoue Tadashi
Nagayama Satoshi
Nakao Kazunari
Ashbrook Charles W.
Kurlandsky David R.
Nwaonicha Chukwuma
Page Thurman K.
Pfizer Inc.
LandOfFree
Substituted N -sulfonylaminobenzyl-2-phenoxyacetamide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted N -sulfonylaminobenzyl-2-phenoxyacetamide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted N -sulfonylaminobenzyl-2-phenoxyacetamide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825323